5-year intensive proof-of-concept trial on therapeutic vaccination (Remune) and intermittent HAART after HAART intensification and GM-CSF use in chronic HIV disease (CTN 140 study)
Emil Toma (Invited speaker), M Loignon (Speaker), D Zarowny (Speaker), A Thorne (Speaker), NF Bernard (Speaker), L-G Labrecque (Speaker), C Tremblay (Speaker), L Cyr (Speaker), M-P Cordeau (Speaker), Sindhu, S. (Speaker), José Menezes (Speaker), R Beaulieu (Speaker)
Activity: Talk or presentation types › Oral presentation